In a recent episode of the Pharma Conversations podcast, Kevin O’Donnell of the Health Products Regulatory Authority (HPRA) offered a detailed and thought-provoking ...

Solstice Advanced Materials outlines its perspective on the transition to lowGWP propellants in an interview with International Pharmaceutical Industry Journal, ...

International Pharmaceutical Industry Journal speaks with Michele Guasti, Global Product Manager at Terumo Pharmaceutical Solutions Division. The discussion explores...

Few regulatory issues have the potential to reshape pharmaceutical manufacturing as profoundly as PFAS. Often referred to as "forever chemicals", per- and polyfluoro...

Typically, global companies developing innovative therapies are familiar with the differences between regulatory systems in the United States and European Union. In ...

The EU’s Health Technology Assessment Regulation (EU-HTAR) aims to introduce more harmonised, efficient and evidencebased assessments of new health technologies. How...

Patient centricity has become one of the most widely shared ambitions in clinical research. The industry increasingly recognises that engaging patients early in deve...

The global skincare market represents a multi-hundred-billion-dollar industry, with continued growth projected over the coming decade. A significant portion of this ...

Driven by complex modalities, global supply chains, and strategic partnerships, increased outsourcing makes tech transfer a critical process for both CDMOs and spons...

Understandably, much of the last few years – and the rise of peptides – has been completely dominated by one or two products, namely the now ubiquitous GLP-1 drugs f...